Prevention asked me about the study behind a striking headline: low-dose aspirin may lower dementia risk by about 70%, but only in people with a certain genetic profile.1 That number does come from the paper. It is also only half of the result. Here is what I told the magazine:
“The key point in this study is that bleeding roughly doubled in exactly the group that appeared to benefit. That trade-off is the whole story.”
This is the longer version: what the researchers found, why your last blood test can’t tell you whether it applies to you, and who should stay away from daily aspirin.
What the study found
ASPREE was a randomized trial of 100 mg of aspirin a day versus placebo in 19,114 healthy older adults in Australia and the United States, aged 70 or older (65 or older for U.S. minorities). Over a median of 4.7 years, aspirin made no meaningful difference to dementia, probable Alzheimer’s disease, mild cognitive impairment or cognitive decline.2
The new analysis, published in Alzheimer’s & Dementia in September 2026, went back to the 13,541 participants with usable genetic data.3 A polygenic score adds up the small effects of many genetic variants into one estimate of a person’s inherited tendency toward a trait. The researchers started with 5,182 of these scores, tested the 1,848 that passed quality checks, and looked for any that changed how aspirin worked. The strongest signal came from scores for platelet count.
| Top 20% of the platelet score (2,708 people) | Aspirin (1,310 people) | Placebo (1,398 people) |
|---|---|---|
| Developed dementia | 13 (1.0%) | 46 (3.3%) |
| Major bleeding | 58 (4.4%) | 29 (2.1%) |
In that top fifth, people assigned to aspirin had about 70% less dementia (hazard ratio 0.28, 95% CI 0.15 to 0.52) and about twice the major bleeding (hazard ratio 2.13, 95% CI 1.36 to 3.34).3 In the other 80% of participants, aspirin showed no dementia benefit. In the lowest fifth the estimate leaned the wrong way, though not significantly (hazard ratio 1.36, 95% CI 0.85 to 2.20), and the authors say they can’t rule out harm in people with lower scores.
The benefit and the harm were the same size
A 70% reduction sounds enormous because it is a relative number. In absolute terms, dementia fell by about 2.3 percentage points and major bleeding rose by about 2.3 percentage points. By the authors’ calculation, about 44 people would need to take aspirin to prevent one case of dementia, and about 44 would need to take it to cause one major bleed. Put another way, that is about five fewer dementia cases and five more major bleeds per 1,000 person-years.3 Major bleeding here means clinically significant bleeding, hemorrhagic stroke or subarachnoid hemorrhage. Deaths from any cause did not differ between aspirin and placebo in this group.
“The benefit and the harm were essentially the same size in absolute terms, and the finding needs replication and a dedicated trial before it changes anyone’s care.”
Why your last blood test can’t answer this
The score measures an inherited tendency toward a higher platelet count. It is not the platelet number on your lab report, and someone in the high-score group may have a perfectly normal count. Measured platelet counts weren’t available for this analysis, so there is no lab value to translate the finding into.3
It also works the other way. A high platelet count on routine bloodwork usually reflects something temporary, like iron deficiency, inflammation, infection or recovery from surgery. In two large case series of adults, 88% to 97% of high counts were reactive, meaning the bone marrow was responding to something else.4 Nobody should look at their last complete blood count and draw conclusions from this study.
A platelet count that stays high without a clear reason still deserves a workup, because a minority of cases come from a bone marrow disorder such as essential thrombocythemia.4 That is a separate question from this study.
Can you find out your score?
Not in any useful way yet. Genetic testing that includes polygenic scores is becoming more widely available, so it isn’t far-fetched that a doctor could offer something like this one day. But this finding isn’t ready to act on, for several reasons:3
- It is exploratory. This is a post hoc subgroup of an existing trial, and the authors themselves call it hypothesis-generating.
- The effect may be overstated. Picking the strongest signal out of 1,848 scores can inflate the estimate, and the case counts are small: 13 versus 46.
- Replication will be hard. The authors note that, to their knowledge, ASPREE is the only large placebo-controlled aspirin prevention trial with both dementia outcomes and genetic data.
- Follow-up was short for dementia. The median was under five years, for a disease that develops over many more.
- Almost all participants (96.6%) were of European ancestry. Polygenic scores generally predict less accurately in people of other ancestries.5
As I told Prevention, replication is “realistically years away,” and “I’d discourage people from running consumer DNA files through online calculators to self-diagnose.” The American College of Medical Genetics and Genomics makes a similar general point: a polygenic score is a statistical prediction rather than a diagnosis, and a patient and clinician should discuss how the result will be used before the test is done.6
Who should not start aspirin
Regular aspirin raises the risk of internal bleeding, mainly in the stomach and, rarely but seriously, in the brain. Across the whole ASPREE trial, major hemorrhage ran at 8.6 events per 1,000 person-years on aspirin versus 6.2 on placebo, with no significant reduction in cardiovascular disease.7 The U.S. Preventive Services Task Force recommends against starting low-dose aspirin for primary prevention of cardiovascular disease in adults 60 and older, and this study doesn’t change that.8
Bleeding risk on aspirin rises with:
- Older age
- A history of ulcers or gastrointestinal bleeding
- Kidney disease
- Uncontrolled blood pressure
- Heavy alcohol use
- Other medications, including blood thinners, NSAIDs like ibuprofen or naproxen, SSRIs and steroids
One important exception: all of this is about starting aspirin to prevent a first problem. If you take aspirin because of a heart attack, stroke, stent or another condition your doctor is treating, this study isn’t about you. Don’t stop it without talking to your doctor.8
What lowers dementia risk today
You don’t need a genetic test to act on most dementia risk. The 2024 Lancet Commission linked about 45% of dementia cases to 14 modifiable risk factors, including high blood pressure, high LDL cholesterol, diabetes, hearing and vision loss, physical inactivity, smoking, heavy drinking, depression and social isolation.9 I went through how a routine visit can cover these in what a brain health checkup should include, and cholesterol risk in particular often needs a closer look than a standard panel gives, as I explain in why normal cholesterol isn’t enough.
The bottom line
“This study is an exciting proof of concept for precision prevention,” I told Prevention. “A drug that looks useless on average may help a specific, genetically identifiable group, and that is the direction longevity medicine is heading.” For now it is a reason to run a trial, not a reason to take aspirin. Please don’t start daily aspirin to protect your brain because of this study, and don’t stop aspirin your doctor prescribed. If you want an unhurried look at your own dementia and bleeding risk, start with a free discovery call, or read more about what a longevity doctor does.
Frequently asked questions
Does low-dose aspirin prevent dementia?
Not for most people. The ASPREE trial of 19,114 healthy older adults found no meaningful difference in dementia, probable Alzheimer’s disease or mild cognitive impairment between aspirin and placebo. A 2026 genetic analysis of the same trial found about 70% less dementia on aspirin in people in the top 20% of a platelet-count genetic score, but major bleeding doubled in that group and the other 80% saw no benefit. The finding still needs replication.
Should I start taking aspirin to lower my dementia risk?
Not on the basis of this study. Even in the group that appeared to benefit, the harm was about the same size as the benefit: about 44 people would need to take aspirin to prevent one dementia case, and about 44 to cause one major bleed. The U.S. Preventive Services Task Force also recommends against starting low-dose aspirin for cardiovascular prevention at age 60 or older. Talk with your doctor before starting aspirin for any reason.
Does a high platelet count on my blood test mean aspirin would help me?
No. The study used a genetic score, not a measured platelet count, and someone with a high score can have a perfectly normal count. A high count on routine bloodwork usually reflects something temporary, such as iron deficiency, inflammation, infection or recovery from surgery. If your count stays high without a clear reason, ask your doctor about a workup.
Can I find out whether I have the high-platelet genetic score?
Not through a routine checkup, and it would not change what you should do today. The score has not been externally validated for deciding who should take aspirin. I discourage running consumer DNA files through online calculators to self-diagnose. Polygenic scores are statistical predictions, not diagnoses, and they generally predict less accurately in people of non-European ancestry.
I already take daily aspirin. Should I stop?
Not without talking to your doctor. If you take aspirin because of a heart attack, stroke, stent or another condition, this study does not apply to you. If you take it on your own to prevent a first problem, it is worth asking your doctor whether the benefit still outweighs the bleeding risk, especially if you are 60 or older or take other medications that raise bleeding risk.
References
Blanton K. “This Common OTC Drug May Lower Your Dementia Risk by 70%—but There’s an Important Catch.” Prevention, November 4, 2026. Quotes Dr. Luke Sorrell. prevention.com
Ryan J, Storey E, Murray AM, et al. “Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline.” Neurology 95, no. 3 (2020): e320–e331. DOI: 10.1212/WNL.0000000000009277
Fransquet PD, Yu C, Tran C, et al. “Platelet count polygenic scores may modify the effect of aspirin in primary prevention of dementia.” Alzheimer’s & Dementia 22, no. 9 (2026): e71817. DOI: 10.1002/alz.71817
Bleeker JS, Hogan WJ. “Thrombocytosis: diagnostic evaluation, thrombotic risk stratification, and risk-based management strategies.” Thrombosis 2011 (2011): 536062. DOI: 10.1155/2011/536062
Martin AR, Kanai M, Kamatani Y, et al. “Clinical use of current polygenic risk scores may exacerbate health disparities.” Nature Genetics 51, no. 4 (2019): 584–591. DOI: 10.1038/s41588-019-0379-x
Abu-El-Haija A, Reddi HV, Wand H, et al. “The clinical application of polygenic risk scores: A points to consider statement of the American College of Medical Genetics and Genomics (ACMG).” Genetics in Medicine 25, no. 5 (2023): 100803. DOI: 10.1016/j.gim.2023.100803
McNeil JJ, Wolfe R, Woods RL, et al. “Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly.” New England Journal of Medicine 379, no. 16 (2018): 1509–1518. DOI: 10.1056/NEJMoa1805819
US Preventive Services Task Force. “Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement.” JAMA 327, no. 16 (2022): 1577–1584. DOI: 10.1001/jama.2022.4983
Livingston G, Huntley J, Liu KY, et al. “Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission.” The Lancet 404, no. 10452 (2024): 572–628. DOI: 10.1016/S0140-6736(24)01296-0